Loading company
Metagenomi Therapeutics, Inc.
MGX · Nasdaq · ·
Next earnings: November 10, 2026
$1.14-0.4%Sep 29 close
- 1M
- -4.6%
- 6M
- -10.3%
- 1Y
- -52.1%
MGX · Nasdaq · ·
Next earnings: November 10, 2026
$1.14-0.4%Sep 29 close
Metagenomi Therapeutics, Inc. is scheduled to report next on November 10, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending March 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toMar 31, 2026 | 3 months toMar 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $1.2M | $4.1M | -69.76% |
| Profit | -$27.5M | -$19.9M | -38.05% |
| Profit per share | -$0.73 | -$0.54 | -35.19% |
| Free Cash Flow | -$19.6M | -$21.4M | +8.14% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“During the second quarter, we continued to execute against our strategic priorities while advancing toward our planned regulatory submissions for our MGX-001 program in hemophilia A later this year,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
The quote and the company description come from Metagenomi Therapeutics, Inc.’s Item 2.02 8-K filed August 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Metagenomi Therapeutics, Inc. has no earnings call transcript available.